Biotech

All Articles

Analysts dig into Avidity's DMD win, disclosing subtleties in information

.Avidity Biosciences pleased clients with period 1/2 records in Duchenne muscular dystrophy (DMD) Fr...

Actinogen's cortisol blocker fails period 2 depression research

.Actinogen Medical's cortisol blocker has actually missed the major endpoint of a phase 2 research i...

Bivictrix makes a decision going exclusive only means to take ADC into center

.Antibody-drug conjugates (ADCs) have been at the facility of numerous a billion-dollar biobuck lice...

TPG leadings up funds to $580M for expenditures across lifestyle scientific researches

.Asset supervisor TPG, which has actually sustained biotechs including Sionna Therapeutics and Santa...

Merck quits phase 3 TIGIT test in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT system has actually gone through an additional obstacle. Months after shutte...

After a tough year, Exscientia folds in to Recursion

.After a year defined by pipeline cuts, the variation of its own chief executive officer and layoffs...

Cullinan, after $25M package, hands back bispecific to Harbour

.Cullinan Therapeutics was blown away good enough along with Port BioMed's bispecific invulnerable a...

A closer check out Strong Biotech's Tough 15

.In this particular week's incident of "The Best Line," our company are actually diving right into F...

Lilly experiences period 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's gathering commemorating the approval of Alzh...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of notable management hirings, firings as well a...